Secukinumab Reduces Erosions in Psoriatic Arthritis Patients

Key Takeaways

• Secukinumab reduced erosion volume in psoriatic arthritis (PsA) patients over 48 weeks.
• Enthesiophyte progression was less likely with secukinumab treatment (OR: 0.264; P = 0.030).
• Odds of partial erosion healing were 2.9 times higher with secukinumab.

Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial.

The study evaluated the impact of the IL-17A inhibitor secukinumab on erosion and enthesiophyte progression. The researchers used high-resolution peripheral quantitative computed tomography (HR-pQCT) in 40 PsA patients with at least one erosion in the metacarpophalangeal joints. Patients were randomized to receive subcutaneous secukinumab or placebo over 48 weeks.

At weeks 24 and 48, the secukinumab group showed significant reductions in erosion volume compared to the placebo group (P = 0.004). Enthesiophyte progression odds were also reduced in the secukinumab group (OR = 0.264; 95% CI: 0.080 to 0.878; P = 0.030). Partial erosion healing odds were significantly higher in the secukinumab group (OR = 2.882; 95% CI: 1.130 to 7.349; P = 0.027).

“These findings support secukinumab’s role in managing structural damage in PsA,” the researchers concluded."

Source: Jin Y, et al. Arthritis and Rheumatology. 2025. Doi:10.1002/art.43154